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Role of 1% alendronate gel as 
adjunct to mechanical therapy in the 
treatment of chronic periodontitis 
among smokers
Objective: Alendronate (ALN) inhibits osteoclastic bone resorption and 
triggers osteostimulative properties both in vivo and in vitro, as shown by 
LQFUHDVHLQPDWUL[IRUPDWLRQ7KLVVWXG\DLPHGWRH[SORUHWKHHI¿FDF\RI
ALN gel as local drug delivery (LDD) in adjunct to scaling and root planing 
(SRP) for the treatment of chronic periodontitis among smokers. Material and 
Methods: 75 intrabony defects were treated in 46 male smokers either with 
1% ALN gel or placebo gel. ALN gel was prepared by adding ALN into carbopol-
GLVWLOOHGZDWHUPL[WXUH&OLQLFDOSDUDPHWHUV>PRGL¿HGVXOFXVEOHHGLQJLQGH[
plaque index, probing depth (PD), and periodontal attachment level (PAL)] 
were recorded at baseline, at 2 months, and at 6 months, while radiographic 
SDUDPHWHUVZHUHUHFRUGHGDWEDVHOLQHDQGDWPRQWKV'HIHFW¿OODWEDVHOLQH
and at 6 months was calculated on standardized radiographs by using the 
image analysis software. Results: Mean PD reduction and mean PAL gain 
were found to be greater in the ALN group than in the placebo group, both 
DWDQGPRQWKV)XUWKHUPRUHDVLJQL¿FDQWO\JUHDWHUPHDQSHUFHQWDJH
RIERQH¿OOZDVIRXQGLQWKH$/1JURXSFRPSDUHGWRWKH
SODFHERJURXS&RQFOXVLRQV7KHUHVXOWVRIWKLVVWXG\VKRZHG
$/1VWLPXODWHGDVLJQL¿FDQWLQFUHDVHLQ3'UHGXFWLRQ3$/JDLQDQGDQ
LPSURYHGERQH¿OOFRPSDUHGWRSODFHERJHOLQFKURQLFSHULRGRQWLWLVDPRQJ
smokers. Thus, 1% ALN, along with SRP, is effective in the treatment of 
chronic periodontitis in smokers.
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Introduction
%DFWHULDOELR¿OPKDVEHHQFRQVLGHUHGRQHRIWKH
main aetiological factors in periodontal diseases10. 
Additionally, extensive researches suggest that host-
derived enzymes, cytokines, and other mediators play 
a direct role in extracellular matrix (ECM) destruction 
in periodontitis20. The bacteria, therefore, initiate 
disease by activating host mechanisms that then 
destroy the supporting structures of the periodontium. 
This justifies how initiation and progression of 
periodontal diseases can be inhibited by interfering 
with host factors.
Conventionally, periodontal disease is treated by 
mechanical periodontal therapy, but certain cases 
may require adjunctive chemical periodontal therapy. 
Chemical periodontal therapy may involve various 
host modulators for controlling periodontal tissue 
destruction.
Bisphosphonates (BPs) are carbon-substituted 
pyrophosphate (P-C-P) analogs that include potent 
inhibitors of bone resorption, which have been 
effectively used to control osteolysis or reduce bone 
loss in Paget’s disease, metastatic bone disease, 
hypercalcemia of malignancy1, and osteoporosis16.
Alendronate sodium (ALN) is  an amino 
bisphosphonate and, once taken up by bone, it acts 
as an antiosteolytic agent. ALN binds to resorption 
VXUIDFHVDQGLVORFDOO\UHOHDVHGGXULQJWKHDFLGL¿FDWLRQ
associated with osteoclastic activity. This release leads 
to a rise in the local concentration of ALN, resulting 
in an alteration in the ruffled border membrane 
characteristic of osteoclasts without destroying the 
cells. Therefore, ALN seems to have a potential to be 
used as an inhibitor of alveolar bone resorption in the 
treatment of periodontitis.
Previous studies have shown the effects of systemic 
ALN in human and other animal models in decreasing 
bone loss and increasing alveolar bone density12,15,17. 
Additionally, studies have observed that topical 
application of ALN was highly effective in reducing 
DOYHRODU ERQH UHVRUSWLRQ DIWHUPXFRSHULRVWHDO ÀDS
surgery3,4,22,24,30.
Evidence from cross-sectional and case-control 
studies in various populations and an abundant 
number of reviews on the subject have shown that 
adult smokers are about two to four times more likely 
to have periodontitis than nonsmokers. Previous 
studies indicated that smokers did not respond to non-
surgical periodontal therapy2,13. Additionally, smokers 
showed less probing depth reduction and attachment 
gain, compared to nonsmokers, for periodontal 
surgical treatment11,23.
Considering the abovementioned facts, the current 
VWXG\LVGHVLJQHGWRHYDOXDWHWKHHI¿FDF\RI$/1
gel as local drug delivery along with scaling and root 
planing (SRP) for the treatment of intrabony defects 
among smokers with chronic periodontitis.
Material and methods
Source of data
In this 6 month follow-up longitudinal interventional 
study, a total of 52 male smokers (age range: 30-50 
years old) with chronic periodontitis was selected 
from the outpatient section of the Department of 
Periodontics, Government Dental College & Research 
Institute, Bangalore. The research protocol was 
presented to the Ethical Committee and Review Board 
of the institution. After ethical approval, all subjects 
were verbally informed and written informed consent 
was taken for participation in the research. The study 
was conducted from March 2010 to April 2011.
Selection criteria
Systemically healthy subjects with probing depth 
3'PPRUSHULRGRQWDODWWDFKPHQW OHYHO 3$/
WRPPDQGDUDGLRJUDSKLFYHUWLFDOERQHORVV
mm with no history of periodontal therapy or use of 
antibiotics in the preceding 6 months were included 
in the study. Smoking history was collected by self-
report after a standardized questionnaire. Subjects 
ZHUHFODVVL¿HGDVVPRNHUVDQGQRQVPRNHUVEDVHGRQ
criteria established by the Centers for Disease Control 
DQG3UHYHQWLRQ&'&³FXUUHQWVPRNHUV´ZHUHGH¿QHG
as those who had smoked 100 or more cigarettes over 
their lifetime and smoked at the time of interview; 
“former smokers” had smoked 100 or more cigarettes 
over their lifetime but were not currently smoking; 
and “nonsmokers” had not smoked 100 or more 
cigarettes over their lifetime. Former smokers were 
excluded in an attempt to make a clear discrimination 
between smokers and nonsmokers. Subjects with the 
following characteristics were excluded from the study: 
known systemic disease; known or suspected allergy 
to the ALN/bisphosphonate group; systemic ALN/
bisphosphonate therapy; aggressive periodontitis; 
Role of 1% alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers
2017;25(3):243-9
245J Appl Oral Sci.
use of smokeless tobacco in any form; alcoholism; 
LPPXQRGH¿FLHQF\
46 subjects (out of 52 enrolled), who matched 
clinical and radiographic parameters, were recruited 
for double-blind clinical study (Figure 1). Multiple sites 
from the same patients were also considered in case 
RIIXO¿OOLQJVHOHFWLRQFULWHULD$WRWDORIVLWHVZHUH
randomly (by computer generated system) assigned to 
either ALN or placebo group. 37 sites (2 failed) and 38 
sites (4 failed) completed the study in the ALN group 
and placebo group, respectively. Another clinician (AS) 
treated subjects enrolled to either group. All pre- and 
posttreatment clinical parameters were recorded by 
an examiner (ARP) who was masked to the type of 
treatment received by the subjects, while another 
clinician (AS) provided treatment to both groups.
In the ALN group, sites were treated with SRP 
followed by 1% ALN gel (10 mg/ml) local drug delivery, 
while in the placebo group sites were treated with SRP 
followed by placebo gel placement. Subjects were 
blinded for allocation into ALN or placebo group. SRP 
was performed at baseline until the root surface was 
considered smooth and clean by the operator (AS). No 
DQWLELRWLFVRUDQWLLQÀDPPDWRU\DJHQWZHUHSUHVFULEHG
after treatment. Clinical parameters, including 
PRGL¿HGVXOFXVEOHHGLQJLQGH[P6%,18, full mouth 
DQGVLWHVSHFL¿FSODTXHVFRUH3,28, PD, and PAL, were 
recorded at baseline (before the SRP) and at 2 and 
6 months. A custom-made acrylic stent and a no. 15 
color-coded University of North Carolina periodontal 
probe were used to standardize the measurement of 
clinical parameters.
Intra-examiner calibration
30 sites were examined twice for intra-examiner 
calibration. Calibrations were considered for 
measurements similar to 1 mm at the 95% level.
Radiographic assessment of Intrabony Defects 
(IBD)
%RQH¿OOZDVHYDOXDWHGDWEDVHOLQHDQGDWPRQWKV
using an image analyzer (Scion image Corporation, 
Frederick, MA, USA). IBD was measured on the 
radiograph by measuring the vertical distance from the 
crest of the alveolar bone to the base of the defect. 
Individually customized bite blocks and a parallel-angle 
WHFKQLTXHZHUHXVHGWRREWDLQ¿OPVDVUHSURGXFLEOH
as possible. All radiographs were reviewed in a 
single reference center by a masked evaluator. For 
assessment, radiographs were scanned with a 6400 
DPI scanner (Epson Perfection V700, Bangalore, 
India) by an evaluator who was blinded to the surgical 
procedure performed in the subjects. The radiographic 
IBD depth was measured by computer aided software 
program, as previously used25.
Primary and secondary outcome measures
The primary outcome of the study was PD and 
PAL. The secondary outcomes included complete bone 
GHIHFW¿OO
Formulation of 1% ALN gel
ALN gel was prepared as described by Reddy, et 
al.24%ULHÀ\$/1$SH[3KDUPD$QNOHVKZDU
Gujarat, India) was dissolved in a required amount 
of distilled water to achieve 1% ALN concentration. 
A weighed quantity of carbopol 934P (2% w/w) was 
taken and added to the distilled water. The mixture 
was gradually stirred and carbopol was allowed to soak 
for 2 h. 1% triethanolamine was added to neutralize 
the carbopol solution and to form the gel. The pH 
was adjusted to 6.8. Finally, the required amount of 
methylparaben (0.1%) and propylparaben (0.05%) 
were dissolved in ethanol and added to the gel. The 
placebo gel was prepared by the abovementioned 
procedure without adding the active ingredient (ALN).
Local drug delivery
The prepared ALN gel (10 mg/ml) was dispensed 
into the periodontal pockets with intrabony defects 
using a syringe with a blunt cannula. Patients were 
instructed not to use forceful brushing or interdental 
aids at the treated sites until the appointment after 
2 months and to avoid chewing sticky or hard food.
Statistical analysis
Power analysis calculations were performed before 
the study was initiated. To achieve 90% power and 
detect mean differences of the clinical parameters 
between groups, 30 sites in each group were required. 
The categorical variable (site-specific PI) was 
expressed as percentage and the continuous variable 
(Full mouth PI, mSBI, PD, PAL, and IBD depth), as 
PHDQ  VWDQGDUG GHYLDWLRQ 6LWHVSHFLILF 3, ZDV
compared by using Chi-squared test or Fisher’s exact 
test when the expected frequency was less than 5. 
Normality assumption was tested using Shapiro-Wilk’s 
W test. If the continuous variable followed a normal 
distribution, a comparison would be carried out in 
the treatment group using student’s t test. Statistical 
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VLJQL¿FDQFHZDVGH¿QHGDVS6WDWLVWLFDODQDO\VLV
was performed with SPSS version 15, SPSS Inc., 
Chicago, IL, USA.
Results
46 subjects (multiple sites/subject) out of 52 
completed the study (Figure 1). All subjects tolerated 
the drug well without any complications or adverse 
reactions. Soft tissues healed within normal limits, and 
QRVLJQL¿FDQWYLVXDOGLIIHUHQFHVZHUHQRWHG
%RWKJURXSVVKRZHGLPSURYHPHQWLQVLWHVSHFL¿F
Parameters        
(mm)                             
  Visits     ALN Placebo  t-value† p-value
Probing  depth Baseline
2 Month
6 Month
7.84 ±2.04
5.05 ±1.78
3.68 ±1.93
7.62 ±1.97
6.38 ±1.84
5.57±1.88
0.21
9.87
18.253
0.645
<0.002*
<0.001*
Periodontal 
attachment
level
Baseline
2 Month
6 Month
6.43 ±1.77
4.05 ±1.94
2.49 ±1.53
6.19 ±1.54
5.22 ±1.73
4.41±1.83
0.4
7.36
23.79
0.531
<0.008*
<0.001*
Intrabony  defect 
depth
Baseline
6 Month
5.18 ±1.00
3.07 ±0.94
5.10 ±0.95
4.97 ±0.95
0.123
74.03
0.727
<0.001*
6WDWLVWLFDOO\VLJQL¿FDQWDWS
† t test
Table 1- Probing depth, periodontal attachment level, and intrabony defect depth in alendronate and placebo groups at different time 
interval
Figure 1-6WXG\ÀRZFKDUW
Figure 2- Full mouth plaque scores and gingival index for alendronate and placebo groups at different time intervals
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and full mouth PI score, but improvement was not 
VWDWLVWLFDOO\ VLJQL¿FDQW DPRQJ ERWK JURXSV DW DQ\
WLPH SRLQW IRU VLWHVSHFL¿F 3, ,PSURYHPHQW LQ IXOO
PRXWK3, VFRUHZDV VLJQL¿FDQWO\KLJKHU LQ WKH$/1
JURXSSFRPSDUHGWRWKHSODFHERJURXSDW
months (Figure 2).
In both groups, mSBI showed no difference at 
baseline, at 2 months, and at 6 months (Figure 2).
Clinical parameters PD and PAL showed no 
difference in intergroup comparison at baseline and 
VKRZHGVLJQL¿FDQW3'UHGXFWLRQDQG3$/JDLQDWDQG
PRQWKVDWS7DEOHV
Radiographic parameter IBD showed statistically 
VLJQL¿FDQWPHDQUHGXFWLRQRIPPLQWKH
alendronate group, in comparison to the placebo 
JURXSPP7DEOH$OHQGURQDWHVLWHV
SUHVHQWHG D VLJQL¿FDQWO\ KLJKHU YHUWLFDO GHIHFW ¿OO
WKDQSODFHERVLWHVDW
6 months (Table 2).
Discussion
7KLV VWXG\ KDV HYDOXDWHG WKH FOLQLFDO HI¿FDF\ RI
1% ALN gel along with SRP for the treatment of IBD 
in smokers with chronic periodontitis and showed 
VLJQL¿FDQWUDGLRJUDSKLFERQH¿OODQGLPSURYHPHQWLQ
clinical parameters compared to placebo gel.
ALN and other ingredients of gel formulation 
are approved by the Food and Drug Administration 
(USFDA) for oral uses. Studies24,26 have explored 
different properties for various concentrations of ALN 
and found 1% ALN gel is the optimum dosage for LDD, 
thus 1% ALN was the choice for the current research.
ALN is a bisphosphonate that acts as a potent 
inhibitor of bone resorption. It is now generally 
accepted that the main cell by which bisphosphonates 
mediate their action is the osteoclast. Various 
mechanisms to be involved are inhibition of osteoclast 
recruitment, osteoclast adhesion, osteoclast activity, 
and shortening of osteoclast lifespan (apoptosis)5. 
Several reports have shown that bisphosphonates 
not only induce osteoblasts to secrete inhibitors of 
osteoclast-mediated resorption, but also stimulate the 
formation of osteoblast precursors and mineralized 
nodules, thereby promoting early osteoblastogenesis7.
Histometric analyses showed more percentage of 
bone in the furcation area that was treated with 1 mL 
sodium ALN irrigation (10-5 M), when compared to 
control groups of experimental periodontitis in rats at 
7 and 15 days3. Immunohistochemical analyses also 
expressed stronger osteoprotegerin immunolabeling, 
weaker receptor activator of nuclear factor-kB ligand 
immunolabeling, and fewer tartrate-resistant acid 
phosphatase-positive cells in rats3. Collectively, this 
VWXG\ VKRZHG VLJQV RI VKLIW IURP LQÀDPPDWLRQ WR
periodontal health.
To our knowledge, there have been no studies 
reporting the use of 1% ALN gel as LDD in the treatment 
of chronic periodontitis in smokers. Therefore, a 
direct comparison with other studies is not possible. 
Comparing changes in clinical and radiographic 
parameters with 1% ALN gel as the local drug 
delivery used in the treatment of subjects with CP and 
aggressive periodontitis (AgP) in previous studies26,27, 
the improvement in clinical parameters in this study 
was  higher in AgP subjects but lower in subjects 
ZLWK&3ZKLOHUDGLRJUDSKLFERQH¿OOZDVKLJKHULQ&3
subjects but lower in AgP subjects. PD reduction was 
ORZHULQ&3VXEMHFWVPP
as reported in previous study26, but greater compared 
WR $J3 VXEMHFWV PP DW PRQWKV DV
observed in previous study27. Similarly, PAL gain was 
ORZHULQ&3VXEMHFWVPP
EXW JUHDWHU FRPSDUHG WR $J3 VXEMHFWV 
mm) at 6 months. Conversely, percentage change in 
Clinical parameters % change from 
baseline
ALN group Placebo group  t- value† p- value
Mean PD 2 Month
6 Month
2.78 ± 1.20
4.16 ± 1.23
1.24± 0.83
2.05± 0.94
41.01
68.1
<0.001*
<0.001*
Mean PAL 
(mm)
2 Month
6 Month
2.38 ± 0.95
3.95 ± 0.88
 0.97 ± 0.92
1.78 ±1.22
41.317
75.789
<0.001*
<0.001*
Mean IBD (mm) 6 Month 2.10 ± 0.69  0.12 ± 0.04 302.01 <0.001*
%RQHGHIHFW¿OO 6 Month 41.05 ±11.40 2.5 ± 0.93 420.07 <0.001*
6WDWLVWLFDOO\VLJQL¿FDQWDWS
† t test
Table 2- &KDQJH LQPHDQ SURELQJ GHSWK SHULRGRQWDO DWWDFKPHQW OHYHO DQG LQWUDERQ\ GHIHFW DQG SHUFHQWDJH FKDQJH LQ ERQH ¿OO LQ
alendronate and placebo groups from baseline
SHARMA A, RAMAN A, PRADEEP AR
2017;25(3):243-9
248J Appl Oral Sci.
ERQH¿OOZDVQHDUO\HTXDOEXW ORZHU
LQ$J3VXEMHFWVDQGQHDUO\HTXDOEXW
JUHDWHULQ&3VXEMHFWV26,27.
The results of our study are in line with previous 
studies that have reported that ALN was highly 
effective in reducing alveolar bone resorption 
IROORZLQJPXFRSHULRVWHDOÀDSVXUJHU\24,30. This study 
IRXQGD SHUFHQWDJHRI ,%'¿OO LQ WKH$/1JURXSRI
 FRPSDUHG WR  LQ WKH
placebo group at 6 months. This is in accordance 
with our previous studies26,27. ALN LDD also showed 
VLJQL¿FDQW SHUFHQWDJH RI ERQH ¿OO 
FRPSDUHG WRDWRUYDVWDWLQ /''  LQD
recent clinical trial22. Considering the abovementioned 
facts and results of previous studies, it can be proposed 
that direct subgingivally placed ALN will be a better 
approach for periodontal healing of bony defects in 
smokers with chronic periodontitis. The probable 
PHFKDQLVP IRUEHWWHUERQH¿OO LQ WKHFXUUHQWVWXG\
can be explained by the fact that tobacco components 
have shown to have direct effects on certain bone 
resorptive mediators. Tappia, et al.29 (1995) reported 
that smokers exposed to bacterial lipopolysaccharide 
KDGVLJQL¿FDQWO\KLJKHUSODVPDOHYHOVRI71)DOSKDDQG
IL-6 than nonsmokers, while other study  reported that 
abrogation of interleukin-6 production by alendronate 
in human osteoblastic cells can occur, which could also 
affect osteoclastic activity8.
This study has considered the technique of 
subgingivally delivering ALN directly into pockets of 
smokers with chronic periodontitis as the local drug 
delivery systems that offers the advantages of high 
concentrations at the target site with reduced dosage, 
fewer applications, and high patient acceptability9. 
Compared to a systemic regimen, local delivery may 
RIIHULPSRUWDQWEHQH¿WVLQWHUPVRIDGYHUVHUHDFWLRQV
and patient compliance, as also reported in previous 
study19,26,27.
7KHFXUUHQWVWXG\UHSRUWHGSUHVHQFHRIERQH¿OO
after 6 months from baseline, while ALN was found 
WREHSUHVHQWLQJLQJLYDOFUHYLFXODUÀXLGVDPSOHRQO\
at 1 month and absent at 2 months, as reported 
in a previous study26. This can be explained by the 
release of BPs from bounded bone mineral during bone 
resorption by osteoclasts. This could lead to a localized 
accumulation of BPs, which could directly perturb 
osteoclastic activity or indirectly target osteoblasts 
and macrophages, resulting in decreased osteoclastic 
chemotaxis and activity6. Carbopol was used as vehicle 
for preparation of ALN gel in this study, which is 
considered to provide intimate contact and prolong 
the residing time of a dosage form in the periodontal 
SRFNHW E\ VSHFL¿F LQWHUIDFLDO IRUFHV LQ D SURFHVV
commonly referred as mucoadhesion, after LDD14,21.
Conclusion
7KLVVWXG\VKRZHG$/1JHOFDXVHGVLJQL¿FDQW
improvement in periodontal clinical parameters in 
smokers with chronic periodontitis compared to control 
subjects. 1% ALN can be used as a local drug delivery 
system along with SRP for nonsurgical management 
of periodontitis.
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